ECSP034850A - Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma - Google Patents
Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la mismaInfo
- Publication number
- ECSP034850A ECSP034850A EC2003004850A ECSP034850A ECSP034850A EC SP034850 A ECSP034850 A EC SP034850A EC 2003004850 A EC2003004850 A EC 2003004850A EC SP034850 A ECSP034850 A EC SP034850A EC SP034850 A ECSP034850 A EC SP034850A
- Authority
- EC
- Ecuador
- Prior art keywords
- hexadeca
- salt
- pharmaceutical compositions
- polymorphs
- triazatetraciclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
Abstract
Esta invención se refiere a la sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02, 11.04,9] hexadeca-2 (11), 3,5,7,9-pentaeno. Y a las composiciones farmacéuticas de la misma. En particular, la presente invención se refiere a la sal L-tartrato y además a los diversos polimorfos de la sal L-tartrato, incluyendo dos polimorfos anhidros distintos (denominados en este documento Formas A y B) y un polimorfo hidratado (denominado en este documento Forma C). Además, la presente invención también se refiere a la sal D-tartrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y a los diversos polimorfos de la misma; así como a la sal D,L-tartrato de dicho compuesto y a sus polimorfos, y a la sal meso-tartrato de dicho compuesto y a sus polimorfos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29086101P | 2001-05-14 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034850A true ECSP034850A (es) | 2003-12-24 |
Family
ID=23117845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004849A ECSP034849A (es) | 2001-05-14 | 2003-11-14 | Sales tartrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma |
| EC2003004850A ECSP034850A (es) | 2001-05-14 | 2003-11-14 | Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004849A ECSP034849A (es) | 2001-05-14 | 2003-11-14 | Sales tartrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma |
Country Status (47)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386024T1 (de) * | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| SI1448235T1 (sl) * | 2001-11-30 | 2007-08-31 | Pfizer Prod Inc | Peroralni farmacevtski sestavki s podaljšanim sproščanjem 5,8,14-triazatetraciklo (10.3.1.0(2,11).0(4,9)) -heksadeka-2(11)3,5,7,9-pentaena |
| WO2004103372A1 (en) * | 2003-05-20 | 2004-12-02 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
| EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| BRPI0512245A (pt) * | 2004-06-30 | 2008-02-19 | Lilly Co Eli | composto, composição farmacêutica, e, uso do composto |
| EP1778669A2 (en) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| CA2583101A1 (en) * | 2004-10-15 | 2006-04-20 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| US20080275051A1 (en) * | 2005-02-24 | 2008-11-06 | Busch Frank R | Preparation of High Purity Substituted Quinoxalines |
| US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20070293702A1 (en) * | 2006-02-21 | 2007-12-20 | Viviana Braude | Novel crystalline forms of armodafinil and preparation thereof |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| BRPI0718600A2 (pt) * | 2006-11-09 | 2013-12-10 | Pfizer Prod Inc | Polimorfos de intermediários nicotínicos. |
| US20090062257A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched varenicline |
| US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
| US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| WO2009109651A1 (en) * | 2008-03-06 | 2009-09-11 | Medichem, S.A. | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE |
| EP2262780A4 (en) * | 2008-03-06 | 2012-01-25 | Reddys Lab Ltd Dr | TARTRATE OF VARENICLINE AMORPHOUS |
| JP2011516489A (ja) | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| US8039620B2 (en) | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
| US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
| US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
| WO2010005643A1 (en) * | 2008-07-10 | 2010-01-14 | Teva Pharmaceutical Industries Ltd. | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| EP2334679A1 (en) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
| EP2440187A2 (en) | 2009-06-10 | 2012-04-18 | Actavis Group PTC ehf. | Amorphous varenicline tartrate co-precipitates |
| US8178537B2 (en) | 2009-06-22 | 2012-05-15 | Teva Pharmaceutical Industries Ltd. | Solid state forms of varenicline salts and processes for preparation thereof |
| US20130101630A1 (en) | 2010-03-09 | 2013-04-25 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| EP2837632B1 (en) | 2012-04-13 | 2016-05-18 | Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. | Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases |
| KR101663550B1 (ko) * | 2014-06-11 | 2016-10-07 | 조선대학교산학협력단 | 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품 |
| KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
| WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
| WO2021222230A1 (en) | 2020-04-28 | 2021-11-04 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| US20240374609A1 (en) | 2021-08-20 | 2024-11-14 | Viwit Pharmaceuticalco., Ltd. | Nitrosamine impurity, varenicline pharmaceutical composition capable of reducing generation of nitrosamine impurities and preparation and use thereof |
| KR20230068877A (ko) | 2021-11-11 | 2023-05-18 | 주식회사 아울바이오 | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| CN113980020B (zh) * | 2021-11-22 | 2023-05-09 | 浙江车头制药股份有限公司 | 一种酒石酸伐尼克兰晶型的制备方法 |
| EP4452236A2 (en) | 2021-12-23 | 2024-10-30 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
| US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
| EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
| US12018009B2 (en) | 2022-06-14 | 2024-06-25 | Amygdala Neurosciences, Inc. | ALDH-2 inhibitor compounds and methods of use |
| WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
| KR20240115109A (ko) | 2023-01-18 | 2024-07-25 | 주식회사 아울바이오 | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물 |
| IT202300003888A1 (it) | 2023-03-03 | 2024-09-03 | Dipharma Francis Srl | Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina |
| WO2024224270A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Varenicline formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471503A (en) | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
| ATE386024T1 (de) * | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| YU34501A (sh) * | 2000-05-26 | 2003-10-31 | Pfizer Products Inc. | Postupak reaktivne kristalizacije radi povećanja veličine čestica |
-
2002
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko not_active Expired - Lifetime
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 EP EP02722625A patent/EP1392307B1/en not_active Expired - Lifetime
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en not_active Ceased
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
-
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034850A (es) | Sal citrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma | |
| UY30274A1 (es) | Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones | |
| FR18C1027I1 (fr) | Composition fongicide contenant un derive d'amide d'acide | |
| BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
| PL361404A1 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| UY29927A1 (es) | Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones | |
| MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
| ATE369370T1 (de) | Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren | |
| UY30025A1 (es) | Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| DOP2002000422A (es) | Agentes antibacterianos. | |
| CY1106247T1 (el) | Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες | |
| SE0403171D0 (sv) | New compounds | |
| UY27287A1 (es) | Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma | |
| WO2007081597A3 (en) | Peri condensed tricyclic compounds useful as antibacterial agents | |
| ECSP044999A (es) | Agentes antidiabeticos | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| ES2187261B2 (es) | Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos. | |
| EA200600605A1 (ru) | Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств | |
| BRPI0410044A (pt) | forma de dosagem contendo pantoprazol como ingrediente ativo | |
| ECSP067111A (es) | Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica | |
| BRPI0410157A (pt) | bioisostéreos de actinonina | |
| AR028698A1 (es) | Heterociclos hetaril-substituidos | |
| PT1370513E (pt) | Sais de adicao do acido malico de terbinafina | |
| BRPI0406893A (pt) | Derivados de acilaminotiazol, a respectiva preparação e a respectiva utilização como inibidores da produção do peptìdeo betaamilóide |